Eftyhia Vardas

Summary

Affiliation: Johannesburg Hospital
Country: South Africa

Publications

  1. ncbi Indicators of therapeutic effect in FIT-06, a Phase II trial of a DNA vaccine, GTU(®)-Multi-HIVB, in untreated HIV-1 infected subjects
    Eftyhia Vardas
    Lancet Laboratories, Richmond, Johannesburg, South Africa
    Vaccine 30:4046-54. 2012
  2. ncbi External genital human papillomavirus prevalence and associated factors among heterosexual men on 5 continents
    Eftyhia Vardas
    Division of Medical Virology, University of Stellenbosch, South Africa and Lancet Laboratories, Johannesburg, South Africa
    J Infect Dis 203:58-65. 2011

Detail Information

Publications2

  1. ncbi Indicators of therapeutic effect in FIT-06, a Phase II trial of a DNA vaccine, GTU(®)-Multi-HIVB, in untreated HIV-1 infected subjects
    Eftyhia Vardas
    Lancet Laboratories, Richmond, Johannesburg, South Africa
    Vaccine 30:4046-54. 2012
    ..We evaluated the safety, immunogenicity and clinical effect of a novel recombinant plasmid DNA therapeutic HIV-1 vaccine, GTU(®)-multi-HIVB, containing 6 different genes derived from an HIV-1 subtype B isolate...
  2. ncbi External genital human papillomavirus prevalence and associated factors among heterosexual men on 5 continents
    Eftyhia Vardas
    Division of Medical Virology, University of Stellenbosch, South Africa and Lancet Laboratories, Johannesburg, South Africa
    J Infect Dis 203:58-65. 2011
    ..We examined the baseline prevalence of penile, scrotal, and perineal/perianal human papillomavirus (HPV) in heterosexual men (HM). We also evaluated baseline characteristics of HM to assess factors associated with prevalent HPV detection...